Tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate

We are Tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate CAS:1210348-34-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate
CAS.NO:  1210348-34-7
Synonyms:
Edoxaban Intermediate 2
Edoxaban impurity A

Molecular Formula: C16H29N3O7
Molecular Weight: 375.41700

Physical and Chemical Properties:

Specification:
Appearance: White powder
Purity:≥98.0%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
Intermediates of Edoxaban tosylate CAS:480449-71-6.

Tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate


Related News: Developing countries such as China and India have good foundations for undertaking global industrial transfers because of their comparative advantages. With the continuous improvement of China’s fine chemical technology level, the types of products and market shares in China’s undertaking industrial transfer have gradually increased.2-methylpyridin-3-amine Developing countries such as China and India have good foundations for undertaking global industrial transfers because of their comparative advantages. With the continuous improvement of China’s fine chemical technology level, the types of products and market shares in China’s undertaking industrial transfer have gradually increased.Linoleic acid Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database.79-81-2 Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database.In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase.

Related Products
Product Name
dibenzofuran-4,6-bis-(boronic acid) View Details
2-Iodoanisole View Details
1-Bromo-2-chloroethane View Details
2,4-Difluorobenzoic acid manufacturer 2-Bromo-6-nitroaniline manufacturer 4-Amino-3-nitrobenzonitrile manufacturer tert-butyl 4-(2-ethoxycarbonyl-1-benzofuran-5-yl)piperazine-1-carboxylate manufacturer 2,4,6-Trichlorobenzonitrile manufacturer